A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm showed no meaningful clinical differentiation from standard therapies, and the study was unlikely to achieve statistical significance on its primary endpoint. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are encouraged to join the case.

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging that the company made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study. The complaint claims the study's preliminary statistical assumptions were flawed, the treatment arm lacked meaningful clinical differentiation, and the study was unlikely to achieve statistical significance. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are eligible to join the case.

The Portnoy Law Firm has filed a class action lawsuit against Regeneron Pharmaceuticals on behalf of investors who purchased securities between August 1, 2025 and May 15, 2026. The lawsuit alleges that Regeneron made false statements about its Phase III Fianlimab-Libtayo clinical trial, concealing risks and flawed statistical assumptions. The trial ultimately failed to reach statistical significance on its primary endpoint, causing Regeneron's stock to drop approximately 10% on May 15, 2026.

BCC Research's mid-year assessment highlights AI-driven discovery, precision oncology, and connected health as major growth themes in the life sciences sector. Key opportunities include smart inhalers with AI integration, genomic profiling platforms, cardiovascular drug innovations, and in vitro toxicity testing. The sector benefits from aging populations, regulatory support for non-animal testing, and emerging market expansion, though risks include patent expirations and reimbursement variability.

The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals after its Phase 3 clinical trial for a melanoma therapy failed to reach statistical significance. The lawsuit alleges the company made false and misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the treatment arm was not achieving meaningful differentiation. The stock plunged following the May 15, 2026 announcement, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026.

The Schall Law Firm is seeking investors to join a class action lawsuit against Regeneron Pharmaceuticals for securities fraud. The company allegedly made false and misleading statements about its Phase III Fianlimab-Libtayo study, claiming it was likely to succeed when it actually failed to demonstrate clinical differentiation from competing therapies. Investors who purchased securities between August 1, 2025 and May 15, 2026 are encouraged to participate before the September 14, 2026 deadline.

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made false statements about trial progress while concealing that preliminary statistical assumptions were flawed and the treatment showed no meaningful differentiation over standard therapies. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026.

A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly misleading investors about the success of its Phase III Fianlimab-Libtayo clinical trial. The stock dropped 6.2% on April 29, 2026, and 9.8% on May 15, 2026, after the company announced the study failed to achieve statistical significance. Investors have until September 14, 2026, to request lead plaintiff status.

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026, with a lead plaintiff deadline of September 14, 2026.

A class action lawsuit has been filed against Regeneron Pharmaceuticals alleging securities fraud. The complaint claims the company made false statements about its Phase III Fianlimab-Libtayo study, including flawed statistical assumptions and failure to disclose that the study was unlikely to achieve its primary endpoint. Investors who purchased Regeneron securities between August 1, 2025 and May 15, 2026 are eligible to join the case.

The Portnoy Law Firm has filed a class action lawsuit on behalf of Regeneron Pharmaceuticals investors who purchased securities between August 1, 2025 and May 15, 2026. The lawsuit alleges that Regeneron made false statements about its Phase III Fianlimab-Libtayo clinical trial, misrepresenting the study's prospects while downplaying risks. The trial ultimately failed to reach statistical significance on its primary endpoint, causing Regeneron's stock to drop approximately 10% on May 15, 2026.